Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of riliprubart (SAR445088) in CIDP
CTR20250793Phase 3Active
- Sponsor
- 不适用/ 赛诺菲（中国）投资有限公司
- Start
- Apr 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by 不适用/ 赛诺菲（中国）投资有限公司. Started Apr 2025; status: active.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on CTR20250793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250793.